Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

被引:616
作者
Todo, Yukiharu [3 ]
Kato, Hidenori [3 ]
Kaneuchi, Masanori [2 ]
Watari, Hidemichi [2 ]
Takeda, Mahito [2 ]
Sakuragi, Noriaki [1 ,2 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Gynaecol, Kita Ku, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ Hosp, Dept Gynaecol, Sapporo, Hokkaido 060, Japan
[3] Hokkaido Canc Ctr, Natl Hosp Org, Div Gynaecol Oncol, Sapporo, Hokkaido, Japan
基金
日本学术振兴会;
关键词
PHASE-III TRIAL; THERAPEUTIC ROLE; STAGE-I; CARCINOMA; CHEMOTHERAPY; RISK; ADENOCARCINOMA; RADIOTHERAPY; CORPUS;
D O I
10.1016/S0140-6736(09)62002-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In response to findings that pelvic lymphadenectomy does not have any therapeutic benefit for endometrial cancer, we aimed to establish whether complete, systematic lymphadenectomy, including the para-aortic lymph nodes, should be part of surgical therapy for patients at intermediate and high risk of recurrence. Methods We selected 671 patients with endometrial carcinoma who had been treated with complete, systematic pelvic lymphadenectomy (n=325 patients) or combined pelvic and para-aortic lymphadenectomy (n=346) at two tertiary centres in Japan (January, 1986 June, 2004). Patients at intermediate or high risk of recurrence were offered adjuvant radiotherapy or chemotherapy. The primary outcome measure was overall survival. Findings Overall survival was significantly longer in the pelvic and para-aortic lymphadenectomy group than in the pelvic lymphadenectomy group (HR 0.53, 95% CI 0.38-0.76; p=0.0005). This association was also recorded in 407 patients at intermediate or high risk (p=0.0009), but overall survival was not related to lymphadenectorny type in low-risk patients. Multivariate analysis of prognostic factors showed that in patients with intermediate or high risk of recurrence, pelvic and para-aortic lymphadenectomy reduced the risk of death compared with pelvic lymphadenectomy (0.44, 0.30-0.64; p<0.0001). Analysis of 328 patients with intermediate or high risk who were treated with adjuvant radiotherapy or chemotherapy showed that patient survival improved with pelvic and para-aortic lymphadenectomy (0.48, 0.29-0.83; p=0.0049) and with adjuvant chemotherapy (0.59, 0.37-1.00; p=0.0465) independently of one another. Interpretation Combined pelvic and para-aortic lymphadenectomy is recommended as treatment for patients with endometrial carcinoma of intermediate or high risk of recurrence. If a prospective randomised or comparative cohort study is planned to validate the therapeutic effect of lymphadenectomy, it should include both pelvic and para-aortic lymphadenectomy in patients of intermediate or high risk of recurrence.
引用
收藏
页码:1165 / 1172
页数:8
相关论文
共 25 条
[1]   Role of complete lymphadenectomy in endometrioid uterine cancer [J].
Chan, John K. ;
Kapp, Daniel S. .
LANCET ONCOLOGY, 2007, 8 (09) :831-841
[2]   Therapeutic role of lymph node resection in endometrioid corpus cancer - A study of 12,333 patients [J].
Chan, John K. ;
Cheung, Michael K. ;
Huh, Warner K. ;
Osann, Kathryn ;
Husain, Amreen ;
Teng, Nelson N. ;
Kapp, Daniel S. .
CANCER, 2006, 107 (08) :1823-1830
[3]   Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer [J].
Cragun, JM ;
Havrilesky, LJ ;
Calingaert, B ;
Synan, I ;
Secord, AA ;
Soper, JT ;
Clarke-Pearson, DL ;
Berchuck, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3668-3675
[4]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[5]  
2-8
[6]   The Role of Comprehensive Surgical Staging in Patients With Endometrial Cancer [J].
Frederick, Peter J. ;
Straughn, J. Michael, Jr. .
CANCER CONTROL, 2009, 16 (01) :23-29
[7]   Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer [J].
Fujimoto, Toshio ;
Nanjyo, Hiroshi ;
Nakamura, Akira ;
Yokoyama, Yoshihito ;
Takano, Tadao ;
Shoji, Tadahiro ;
Nakahara, Kenji ;
Yamada, Hidekazu ;
Mizunuma, Hideki ;
Yaegashi, Nobuo ;
Sugiyama, Toru ;
Kurachi, Hirohisa ;
Sato, Akira ;
Tanaka, Toshinobu .
GYNECOLOGIC ONCOLOGY, 2007, 107 (02) :253-259
[8]   CLINICAL STAGE-I ENDOMETRIAL CANCER - PROGNOSTIC FACTORS FOR LOCAL-CONTROL AND DISTANT METASTASIS AND IMPLICATIONS OF THE NEW FIGO SURGICAL STAGING SYSTEM [J].
GRIGSBY, PW ;
PEREZ, CA ;
KUTEN, A ;
SIMPSON, JR ;
GARCIA, DM ;
CAMEL, HM ;
KAO, MS ;
GALAKATOS, AE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (05) :905-911
[9]   Efficacy of systematic pelvic endometrial cancer (MRC ASTEC trial): a randomised study [J].
Kitchener, H. ;
Swart, A. M. C. ;
Qian, W. ;
Amos, C. ;
Parmar, M. K. B. .
LANCET, 2009, 373 (9658) :125-136
[10]   Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology [J].
Lutman, Christopher V. ;
Havrilesky, Laura J. ;
Cragun, Janiel M. ;
Secord, Angeles Alvarez ;
Calingaert, Brian ;
Berchuck, Andrew ;
Clarke-Pearson, Daniel L. ;
Soper, John T. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (01) :92-97